Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 3:34 pm Sale |
2024-09-30 | 13G | VYNE Therapeutics Inc. VYNE |
Soleus Capital Master Fund, L.P. | 0 0.000% |
-703,868 (Position Closed) |
Filing History |
| 2024-02-14 4:57 pm Sale |
2023-12-31 | 13G | VYNE Therapeutics Inc. VYNE |
Citadel Advisors LLC | 1,181,144 8.500% |
-23 (-0.00%) |
Filing History |
| 2024-02-02 09:42 am Sale |
2023-12-31 | 13G | VYNE Therapeutics Inc. VYNE |
Soleus Capital Master Fund, L.P. | 703,868 5.000% |
-187,000 (-20.99%) |
Filing History |
| 2023-11-13 4:41 pm Purchase |
2023-11-01 | 13G | VYNE Therapeutics Inc. VYNE |
Citadel Advisors LLC | 1,181,167 8.500% |
1,181,167 (New Position) |
Filing History |
| 2023-11-13 4:10 pm Purchase |
2023-11-01 | 13G | VYNE Therapeutics Inc. VYNE |
Eventide Asset Management, LLC | 1,394,336 9.990% |
1,394,336 (New Position) |
Filing History |
| 2023-11-13 4:03 pm Purchase |
2023-11-01 | 13G | VYNE Therapeutics Inc. VYNE |
Cormorant Asset Management LP | 1,394,336 9.990% |
1,394,336 (New Position) |
Filing History |
| 2023-11-13 08:24 am Purchase |
2023-11-01 | 13D | VYNE Therapeutics Inc. VYNE |
AI Biotechnology LLC | 3,201,980 19.990% |
3,201,980 (New Position) |
Filing History |
| 2023-11-02 4:15 pm Purchase |
2023-11-01 | 13G | VYNE Therapeutics Inc. VYNE |
Soleus Capital Master Fund, L.P. | 890,868 6.400% |
890,868 (New Position) |
Filing History |
| 2022-02-14 7:33 pm Sale |
2021-12-31 | 13G | VYNE Therapeutics Inc. VYNE |
PERCEPTIVE ADVISORS LLC | 134,756 4.500% |
-142,349 (-51.37%) |
Filing History |
| 2021-08-25 5:04 pm Purchase |
2021-08-17 | 13G | VYNE Therapeutics Inc. VYNE |
PERCEPTIVE ADVISORS LLC | 277,105 9.600% |
277,105 (New Position) |
Filing History |
| 2021-07-09 6:05 pm Purchase |
2021-06-30 | 13G | VYNE Therapeutics Inc. VYNE |
BLACKROCK INC BLK |
57,649 2.000% |
57,649 (New Position) |
Filing History |
| 2021-02-16 4:13 pm Unchanged |
2020-12-31 | 13G | VYNE Therapeutics Inc. VYNE |
GREAT POINT PARTNERS LLC | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2021-02-16 3:39 pm Purchase |
2020-12-31 | 13G | VYNE Therapeutics Inc. VYNE |
PERCEPTIVE ADVISORS LLC | 1,505,323 14.300% |
1,505,323 (New Position) |
Filing History |
| 2021-02-16 3:28 pm Purchase |
2020-12-31 | 13G | VYNE Therapeutics Inc. VYNE |
Point72 Asset Management, L.P. | 1,447 0.100% |
1,447 (New Position) |
Filing History |
| 2021-02-16 2:41 pm Sale |
2020-12-31 | 13G | MENLO THERAPEUTICS INC MNLO |
FIRST MANHATTAN CO | 21,319 0.010% |
-2,146,694 (-99.02%) |
Filing History |
| 2021-02-11 1:56 pm Sale |
2020-12-31 | 13G | MENLO THERAPEUTICS INC MNLO |
JANUS HENDERSON GROUP PLC JHG |
0 0.000% |
-1,281,133 (Position Closed) |
Filing History |
| 2021-02-02 3:13 pm Purchase |
2020-12-31 | 13G | VYNE Therapeutics Inc. VYNE |
BLACKROCK INC BLK |
166,511 7.100% |
166,511 (New Position) |
Filing History |
| 2020-06-11 5:10 pm Purchase |
2020-03-09 | 13G | MENLO THERAPEUTICS INC MNLO |
PERCEPTIVE ADVISORS LLC | 22,876,410 14.000% |
22,876,410 (New Position) |
Filing History |
| 2020-06-11 5:09 pm Sale |
2020-06-09 | 13G | MENLO THERAPEUTICS INC MNLO |
Vivo Capital VIII LLC | 3,643,824 2.200% |
-367,412 (-9.16%) |
Filing History |